Astoria Portfolio Advisors LLC. Sells 24 Shares of Eli Lilly and Company $LLY

Astoria Portfolio Advisors LLC. lessened its stake in Eli Lilly and Company (NYSE:LLY) by 1.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,116 shares of the company’s stock after selling 24 shares during the period. Astoria Portfolio Advisors LLC.’s holdings in Eli Lilly and Company were worth $1,704,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of LLY. Brighton Jones LLC increased its holdings in Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after purchasing an additional 1,730 shares during the period. Revolve Wealth Partners LLC increased its holdings in Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after purchasing an additional 40 shares during the period. Covestor Ltd increased its holdings in Eli Lilly and Company by 24.9% during the 1st quarter. Covestor Ltd now owns 426 shares of the company’s stock valued at $352,000 after purchasing an additional 85 shares during the period. GAMMA Investing LLC increased its holdings in Eli Lilly and Company by 25.8% during the 1st quarter. GAMMA Investing LLC now owns 18,000 shares of the company’s stock valued at $14,866,000 after purchasing an additional 3,696 shares during the period. Finally, Warner Financial Inc. increased its holdings in Eli Lilly and Company by 129.2% during the 1st quarter. Warner Financial Inc. now owns 1,123 shares of the company’s stock valued at $927,000 after purchasing an additional 633 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 1.8%

LLY stock opened at $818.60 on Tuesday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $937.00. The business’s 50 day moving average price is $743.43 and its two-hundred day moving average price is $765.54. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The company has a market capitalization of $774.77 billion, a price-to-earnings ratio of 53.50, a price-to-earnings-growth ratio of 1.18 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $15.56 billion for the quarter, compared to analysts’ expectations of $14.40 billion. During the same period in the previous year, the firm posted $3.92 EPS. The business’s revenue for the quarter was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Insider Transactions at Eli Lilly and Company

In related news, EVP Daniel Skovronsky purchased 1,000 shares of the company’s stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average cost of $634.40 per share, with a total value of $634,400.00. Following the transaction, the executive vice president directly owned 137,660 shares in the company, valued at $87,331,504. This trade represents a 0.73% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gabrielle Sulzberger purchased 117 shares of the company’s stock in a transaction dated Tuesday, August 12th. The stock was bought at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the transaction, the director owned 2,703 shares in the company, valued at approximately $1,733,109.54. This represents a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 4,514 shares of company stock worth $2,894,841. Company insiders own 0.14% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on LLY. Cantor Fitzgerald set a $925.00 price target on Eli Lilly and Company and gave the company an “overweight” rating in a report on Thursday. Daiwa Capital Markets downgraded Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price target on the stock. in a report on Sunday, August 17th. Morgan Stanley reduced their target price on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating on the stock in a report on Friday, October 3rd. Wall Street Zen downgraded Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 20th. Finally, Leerink Partnrs downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $948.06.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.